ZBZ, NCH, AA, JJP, CN, ML, SR, GM and LG have no conflicts of interest that might be relevant to the contents of this manuscript. TD: Consulting: Bayer, Sanofi, Janssen, Astellas. CH: Stock holdings in Johnson and Johnson; research funding to institution from Merck, Bausch Health, Genentech, Bayer, and AstraZeneca, consultant fees from Tempus, Genzyme, and EMD Sorono, speaking fees from OncLive/MJH Life Sciences, travel fees from Merck. PB: Consultant (Institutional): Astellas; Eisai; Janssen, EMD Serono; Dendreon; Pfizer, Seattle Genetics, BMS, Bayer, Exelixis, AVEO Oncology, Guardant Health; Contracted Research (Institutional): AstraZeneca, Merck, AVEO Oncolgy; Research Grant (Institutional): BlueEarth Diagnostics, Exelixis; Speaker’s Bureau (Institutional): Bayer, Caris, Myovant. MAB: MAB has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi and has received grants to his institution from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed as outside of the current study. DK: D Kilari has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Eisai, Pfizer, Merck, Myovant and Sanofi and has received grants to his institution from Astellas, Genentech/Roche and Exelixis for work performed as outside of the current study. Speaker’s Bureau: Janssen. Seagen and Aveo oncology. AT: Honoraria from Urology times, Cardinal Health, Targeted Oncology; Consulting and advisory role at Foundation Medicine, Pfizer,Genzyme, EMD Serono, Exelixis, Seattle Genetics, Deka Biosciences; Instituional research funding from Clovis Oncology, Corvus Pharmaceuticals, Bayer, EMD Serono, Aravive, WindMIL Therapeutics, Bayer, Exact Sciences, Pfizer, Exelixis. RG: Institutional research funding by Endocyte/Advanced Accelerator Applications, Pfizer, Amgen, Immunomedics, Xencor. VSK: Dr. Koshkin has served in a consulting or advisory role for AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seagen, Astellas, Dendreon, Guidepoint, GLG and ExpertConnect; has received research funding for the institution from Endocyte, Nektar, Clovis, Janssen, Seagen and Taiho and is supported by the Prostate Cancer Foundation. VGP: Vaibhav Patel is an employee of Arvinas. He has served as a consultant or advisor for Seagen and Sanofi Genzyme. MS: Paid consultant and/or received Honoria from Sanofi, AstraZeneca, PharmaIn and Resverlogix. He has received research funding to his institution from Zenith Epigenetics, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pfizer, Madison Vaccines, Hoffman-La Roche, Tmunity, SignalOne Bio and Ambrx, Inc. AJA ScM: Paid consultant or advisor for Bayer, Myovant, Pfizer, Janssen, Bayer, Dendreon, Novartis, BMS, Merck, Astrazeneca, Forma, Astellas, Exelixis. Research support to Duke from Bayer, Pfizer, Janssen, Bayer, Dendreon, Novartis, BMS, Merck, Astrazeneca, Forma, Astellas, Amgen. RRM: Institutional research funding from Bayer, Tempus, AstraZeneca. Advisory Board/Consultant for Aveo, AstraZeneca, Bayer, Bristol Myers Squib, Calithera, Caris, Dendreon, Exelixis, Eli Lilly, Janssen, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento Therapeutics, Tempus, Telix. AA: Research funding through institution: MSD; AstraZeneca; Bristol-Myers Squibb; Astellas; Seattle Genetics; Genentech; Pfizer; Progenics; Prometheus; Eli Lilly; ASCO; Celgene; Harpoon Therapeutics.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.